Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766673799> ?p ?o ?g. }
- W2766673799 endingPage "686" @default.
- W2766673799 startingPage "671" @default.
- W2766673799 abstract "Agents targeting programmed death receptor 1 (PD-1) or its ligand (PD-L1) have shown antitumor activity in the treatment of metastatic breast cancer (MBC). The aim of this study was to assess the activity of avelumab, a PD-L1 inhibitor, in patients with MBC.In a phase 1 trial (JAVELIN Solid Tumor; NCT01772004), patients with MBC refractory to or progressing after standard-of-care therapy received avelumab intravenously 10 mg/kg every 2 weeks. Tumors were assessed every 6 weeks by RECIST v1.1. Adverse events (AEs) were graded by NCI-CTCAE v4.0. Membrane PD-L1 expression was assessed by immunohistochemistry (Dako PD-L1 IHC 73-10 pharmDx).A total of 168 patients with MBC, including 58 patients with triple-negative breast cancer (TNBC), were treated with avelumab for 2-50 weeks and followed for 6-15 months. Patients were heavily pretreated with a median of three prior therapies for metastatic or locally advanced disease. Grade ≥ 3 treatment-related AEs occurred in 13.7% of patients, including two treatment-related deaths. The confirmed objective response rate (ORR) was 3.0% overall (one complete response and four partial responses) and 5.2% in patients with TNBC. A trend toward a higher ORR was seen in patients with PD-L1+ versus PD-L1- tumor-associated immune cells in the overall population (16.7% vs. 1.6%) and in the TNBC subgroup (22.2% vs. 2.6%).Avelumab showed an acceptable safety profile and clinical activity in a subset of patients with MBC. PD-L1 expression in tumor-associated immune cells may be associated with a higher probability of clinical response to avelumab in MBC." @default.
- W2766673799 created "2017-11-10" @default.
- W2766673799 creator A5003060935 @default.
- W2766673799 creator A5003411340 @default.
- W2766673799 creator A5008174546 @default.
- W2766673799 creator A5012487596 @default.
- W2766673799 creator A5012750761 @default.
- W2766673799 creator A5022173747 @default.
- W2766673799 creator A5024095268 @default.
- W2766673799 creator A5028539104 @default.
- W2766673799 creator A5030927471 @default.
- W2766673799 creator A5043261380 @default.
- W2766673799 creator A5043591208 @default.
- W2766673799 creator A5050974773 @default.
- W2766673799 creator A5063794457 @default.
- W2766673799 creator A5069003336 @default.
- W2766673799 creator A5070397516 @default.
- W2766673799 creator A5071675004 @default.
- W2766673799 creator A5087769609 @default.
- W2766673799 creator A5089584175 @default.
- W2766673799 date "2017-10-23" @default.
- W2766673799 modified "2023-10-15" @default.
- W2766673799 title "Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study" @default.
- W2766673799 cites W1546771547 @default.
- W2766673799 cites W1820495241 @default.
- W2766673799 cites W1896351481 @default.
- W2766673799 cites W2016983859 @default.
- W2766673799 cites W2019607817 @default.
- W2766673799 cites W2063264144 @default.
- W2766673799 cites W2096322385 @default.
- W2766673799 cites W2100413206 @default.
- W2766673799 cites W2102118972 @default.
- W2766673799 cites W2111225997 @default.
- W2766673799 cites W2117454747 @default.
- W2766673799 cites W2118471749 @default.
- W2766673799 cites W2135601011 @default.
- W2766673799 cites W2136859769 @default.
- W2766673799 cites W2143772132 @default.
- W2766673799 cites W2158348986 @default.
- W2766673799 cites W2170602872 @default.
- W2766673799 cites W2345415641 @default.
- W2766673799 cites W2346775047 @default.
- W2766673799 cites W2402566748 @default.
- W2766673799 cites W2407210580 @default.
- W2766673799 cites W2509486054 @default.
- W2766673799 cites W2510686645 @default.
- W2766673799 cites W2521963431 @default.
- W2766673799 cites W2557730509 @default.
- W2766673799 cites W2560367415 @default.
- W2766673799 cites W2587690704 @default.
- W2766673799 cites W2589148013 @default.
- W2766673799 cites W2597811717 @default.
- W2766673799 cites W2599354912 @default.
- W2766673799 cites W2604441970 @default.
- W2766673799 cites W2738968620 @default.
- W2766673799 cites W2740705517 @default.
- W2766673799 cites W4239622015 @default.
- W2766673799 doi "https://doi.org/10.1007/s10549-017-4537-5" @default.
- W2766673799 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5807460" @default.
- W2766673799 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29063313" @default.
- W2766673799 hasPublicationYear "2017" @default.
- W2766673799 type Work @default.
- W2766673799 sameAs 2766673799 @default.
- W2766673799 citedByCount "508" @default.
- W2766673799 countsByYear W27666737992017 @default.
- W2766673799 countsByYear W27666737992018 @default.
- W2766673799 countsByYear W27666737992019 @default.
- W2766673799 countsByYear W27666737992020 @default.
- W2766673799 countsByYear W27666737992021 @default.
- W2766673799 countsByYear W27666737992022 @default.
- W2766673799 countsByYear W27666737992023 @default.
- W2766673799 crossrefType "journal-article" @default.
- W2766673799 hasAuthorship W2766673799A5003060935 @default.
- W2766673799 hasAuthorship W2766673799A5003411340 @default.
- W2766673799 hasAuthorship W2766673799A5008174546 @default.
- W2766673799 hasAuthorship W2766673799A5012487596 @default.
- W2766673799 hasAuthorship W2766673799A5012750761 @default.
- W2766673799 hasAuthorship W2766673799A5022173747 @default.
- W2766673799 hasAuthorship W2766673799A5024095268 @default.
- W2766673799 hasAuthorship W2766673799A5028539104 @default.
- W2766673799 hasAuthorship W2766673799A5030927471 @default.
- W2766673799 hasAuthorship W2766673799A5043261380 @default.
- W2766673799 hasAuthorship W2766673799A5043591208 @default.
- W2766673799 hasAuthorship W2766673799A5050974773 @default.
- W2766673799 hasAuthorship W2766673799A5063794457 @default.
- W2766673799 hasAuthorship W2766673799A5069003336 @default.
- W2766673799 hasAuthorship W2766673799A5070397516 @default.
- W2766673799 hasAuthorship W2766673799A5071675004 @default.
- W2766673799 hasAuthorship W2766673799A5087769609 @default.
- W2766673799 hasAuthorship W2766673799A5089584175 @default.
- W2766673799 hasBestOaLocation W27666737991 @default.
- W2766673799 hasConcept C121608353 @default.
- W2766673799 hasConcept C126322002 @default.
- W2766673799 hasConcept C143998085 @default.
- W2766673799 hasConcept C197934379 @default.
- W2766673799 hasConcept C2775930923 @default.
- W2766673799 hasConcept C2776694085 @default.
- W2766673799 hasConcept C2777381376 @default.